Coadministration of Posaconazole and Sirolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2016 Apr 26

PMID 27111047

Citations 4

Authors

R Greco

M C Barbanti

M T Lupo Stranghellini

F Giglio

M Morelli

C Messina

A Forcina

C Oltolini

S Piemontese

P Scarpellini

S Marktel

A Assanelli

M Carrabba

L Vago

C Corti

M Bernardi

J Peccatori

F Ciceri

Affiliations

Soon will be listed here.

Citing Articles

Coadministration of isavuconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.

Farina F, Acerbis A, Oltolini C, Chiurlo M, Xue E, Clerici D Ther Adv Infect Dis. 2024; 11:20499361241252539.

PMID: 39351448 PMC: 11440545. DOI: 10.1177/20499361241252539.

Initial sirolimus dosage recommendations for pediatric patients with mutation-related immunodeficiency disease.

Chen X, Wang J, Lan J, Ge X, Xu H, Zhang Y Front Pharmacol. 2022; 13:919487.

PMID: 36188573 PMC: 9515533. DOI: 10.3389/fphar.2022.919487.

Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation.

Zhu L, Huang H, Cai Y, Wang Y, Xu B, Liu M Eur J Clin Pharmacol. 2022; 78(10):1677-1685.

PMID: 36045212 DOI: 10.1007/s00228-022-03378-z.

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study.

Xue E, Lorentino F, Lupo Stanghellini M, Giglio F, Piemontese S, Clerici D J Clin Med. 2022; 11(4).

PMID: 35207379 PMC: 8879643. DOI: 10.3390/jcm11041106.

References

Ullmann A, Lipton J, Vesole D, Chandrasekar P, Langston A, Tarantolo S . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356(4):335-47. DOI: 10.1056/NEJMoa061098. View

De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.... Clin Infect Dis. 2008; 46(12):1813-21. PMC: 2671227. DOI: 10.1086/588660. View

Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L . Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007; 25(34):5471-89. DOI: 10.1200/JCO.2007.12.3851. View

Dolton M, Ray J, Chen S, Ng K, Pont L, McLachlan A . Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012; 56(11):5503-10. PMC: 3486529. DOI: 10.1128/AAC.00802-12. View

Greco R, Oliveira G, Lupo Stanghellini M, Vago L, Bondanza A, Peccatori J . Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol. 2015; 6:95. PMC: 4419602. DOI: 10.3389/fphar.2015.00095. View

Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J . Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009; 48(3):265-73. DOI: 10.1086/595846. View

Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D . Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis. 2009; 49(8):1226-36. DOI: 10.1086/605665. View

Girmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A . Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014; 20(8):1080-8. DOI: 10.1016/j.bbmt.2014.02.018. View

Dolton M, Ray J, Marriott D, McLachlan A . Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012; 56(6):2806-13. PMC: 3370770. DOI: 10.1128/AAC.05900-11. View

10.

Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant T . Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007; 27(6):825-34. DOI: 10.1592/phco.27.6.825. View

11.

Krishna G, Ma L, Martinho M, OMara E . Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012; 56(8):4196-201. PMC: 3421591. DOI: 10.1128/AAC.00222-12. View

12.

Cho E, Chan H, Nguyen H, Shayani S, Nakamura R, Pon D . Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. Pharmacotherapy. 2015; 35(6):578-85. DOI: 10.1002/phar.1600. View

13.

Cornely O, Ullmann A . Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011; 89(3):351-2. DOI: 10.1038/clpt.2010.261. View

14.

Peksa G, Schultz K, Fung H . Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2014; 21(6):409-15. PMC: 5994765. DOI: 10.1177/1078155214539825. View

15.

Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R . Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014; 20(11):O952-9. DOI: 10.1111/1469-0691.12688. View